Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Date:9/11/2012

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD
  • Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012
  • Obesity Collaboration with AstraZeneca:
  • Multiple classes of collaboration compounds have advanced to various stages of development. Though collaboration partner AstraZeneca has decided to discontinue further development of AZD2820, the only compound in clinical trials, AstraZeneca remains committed to this collaboration program and to the continued advancement of collaboration compounds for treatment of obesity.
  • Intellectual property developments:
  • Two additional United States patents have issued in the melanocortin field
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock.
  • Net proceeds to Palatin after deducting offering expenses were $34.5 million 
  • Fourth Quarter and Fiscal Year End 2012 ResultsPalatin reported a net loss of $5.3 million, or $(0.14) per basic and diluted share
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
    (Date:5/21/2015)... 21, 2015 Imagine being able ... and those of others. Being able to read faces ... read people to anticipate their thoughts and actions like ... and feelings to create unique abstract paintings and video, ... Get inside a first-person-shooter as it creates action, dialog, ...
    (Date:5/21/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ) ... Global Survey on Flow Cytometry Adoption Trends" ... goal of this research is to analyze the ... information the survey seeks to collect include factors ... used applications for flow cytometers, respondents, most preferred ...
    (Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ... Technologies in HW_Technical Insights" report to their offering. ... technology trends in the Health and Wellness sector and ... have an impact in the year 2015. The research ... 10 health and wellness technologies that are anticipated to ...
    Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2
    ... and Preclinical-Stage Compounds ... in Merck KGaA ... drug discovery and development company, announced today that,it will collaborate ... discover new applications for drug candidates. KineMed,s,proprietary pathway-based drug discovery ...
    ... CHELMSFORD, Mass., Aug. 28 Magellan Biosciences, ... that,Steven E. Diamond, PhD, has joined the ... to Magellan from Siemens Medical Solutions Diagnostics,(formerly ... research and,development, for the point-of-care product lines: ...
    ... Laboratories, a national,clinical and anatomic pathology reference laboratory ... announced today that it has,renewed a multisource group ... the nation,s largest purchasing alliances of leading,hospitals and ... between ARUP and Premier which has been in ...
    Cached Biology Technology:KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates 2Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer 2Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer 3ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services 2
    (Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
    (Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
    (Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
    Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
    ... abuzz after using fruit flies to find new ways ... cellsresults that could one day be used to advance ... that caffeine interferes with processes in cancer cells that ... in using the stimulant as a chemotherapy treatment. But ...
    ... fish, with an intriguing past, now has had its ... genetic changes that accompanied the adaptation from an aquatic ... by Chris Amemiya, PhD, Director of Molecular Genetics at ... Professor of Biology at the University of Washington, will ...
    ... to ward off viruses by activating a naturally occurring protein ... disrupts the levels of cholesterol required in cell membranes to ... in molecular microbiology and immunology at the Keck School of ... to fight a variety of viral infections. "Previous studies ...
    Cached Biology News:Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3University of Southern California scientists reveal natural process that blocks viruses 2
    MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
    MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
    Normal canine serum collected from healthy normal canines....
    RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
    Biology Products: